Novavax Collaborates with UK Government to Supply 60M Doses of NVX-CoV2373 to Combat COVID-19
Shots:
- Novavax will supply ~60M doses of its COVID-19 vaccine to the UK government for P-III study evaluating the efficacy of NVX-CoV2373 in ~9-000 adults aged 18-85yrs. in the UK. The trial is expected to initiate in Q3’20
- Novavax will expand its collaboration with FUJIFILM Diosynth- which will manufacture the antigen component of NVX-CoV2373 from its Billingham- Stockton-on-Tees site in the UK- in addition to its sites in NC and Texas in the US
- The FUJIFILM Diosynth site in the UK is expected to produce up to 180M doses annually- which boosts the global supply of NVX-CoV2373 for additional markets. NVX‑CoV2373 elicited robust Ab responses superior to seen in human convalescent sera in P-I/II clinical study while P-II study is expected to begin in Aug’2020
Ref: Novavax | Image: Reuters
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected]
